黄芪注射液及其有效成分对乳腺癌细胞增殖和Akt磷酸化的影响

doi:10.3736/jcim20091216

Abstract

Objective

To observe the effects of Astragalus injection, astragaloside Ⅳ and formononetin on proliferation and Akt phosphorylation of basal-like human breast carcinoma cell lines MDA-MB-468 and MDA-MB-231.
Methods

The effects of different concentrations of Astragalus injection, astragaloside Ⅳ and formononetin on proliferation of breast cancer cell lines were assayed by methyl thiazolyl tetrazolium (MTT) assay, and their effects on phospho-Akt were assayed by in-cell Western blot method.
Results

The results of the MTT assay showed that the best concentrations of Astragalus injection, astragaloside Ⅳ, formononetin and astragaloside Ⅳ plus formononetin were 1 g/mL, 80 μg/mL, 40 μg/mL and 10 μg/mL plus 40 μg/mL respectively. After 1- or 2-day culture, Astragalus injection, astragaloside Ⅳ, formononetin and astragaloside Ⅳ plus formononetin decreased the expressions of p-Akt (Thr 308) and p-Akt (Ser 473) in MDA-MB-468 cells. Formononetin and astragaloside Ⅳ plus formononetin down-regulated the expression of p-Akt (Thr 308) protein in MDA-MB-231 cells after 1- and 2-day culture, but had no effects on the expression of p-Akt (Ser 473) protein in MDA-MB-231 cells.
Conclusion

Astragalus injection, astragaloside Ⅳ and formononetin can inhibit proliferation of breast cancer cell lines MDA-MB-468 and MDA-MB-231, and the antiproliferation effects vary according to their concentrations. And the antiproliferation mechanisms may be related to their down-regulation effects on Akt phosphorylation.

Key words: Astragalus injection, Astragaloside F, Formononetin, Breast cancer, Cell proliferation, Phospho-Akt

Ying Deng , Hong-feng Chen. Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines. Journal of Chinese Integrative Medicine, 2009, 7(12): 1174-1180.

/ / Recommend

Add to citation manager EndNote| Reference Manager|ProCite|BibTeX|RefWorks

URL: http://www.jcimjournal.com/EN/10.3736/jcim20091216

http://www.jcimjournal.com/EN/Y2009/V7/I12/1174

TrendMD

Figures/Tables 6

Table 1

Table 2

Figure 1

Figure 2

References 11

[1]	Shen ZZ, Shao ZM. Breast tumor[M]. Shanghai: Shanghai Scientific and Technical Publishers, 2005: 1-2
	沈镇宙, 邵志敏 . 乳腺肿瘤学[M]. 上海: 上海科学技术出版社, 2005: 1-2
[2]	Qin HG . Professor Tang Han-Jun's thinking in syndrome differentiation and experience in treating breast cancer[J]. J Chin Integr Med, 2004,2(4):297-298
	秦海洸 . 唐汉钧教授治疗乳腺癌辨证思路与用药经验[J]. 中西医结合学报, 2004,2(4):297-298
[3]	Lu DM . Qi- and ying-tonifying method for breast cancer patients after mastectomy[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2008,22(1):1-3 doi: 10.3969/j.issn.1008-861X.2008.01.001
	陆德铭 . 益气养阴法为主调治乳腺癌术后患者[J]. 上海中医药大学学报, 2008,22(1):1-3 doi: 10.3969/j.issn.1008-861X.2008.01.001
[4]	Liu PX, Zhou RF, Tan M . Effects of Astragalus injection on proliferation and apoptosis of basal-like breast cancer cell line MDA-MB-231[J]. Zhonghua Ru Xian Bing Xue Za Zhi, 2009,3(2):28-31 doi: 10.3969/j.issn.1674-0807.2009.02.008
	刘鹏熙, 周瑞芳, 谭敏 . 黄芪注射液对basal-like型乳腺癌MDA-MB-231细胞株增殖和凋亡的影响[J]. 中华乳腺病学杂志, 2009,3(2):28-31 doi: 10.3969/j.issn.1674-0807.2009.02.008
[5]	Ye MN, Chen HF . Effects of Astragalus injection on proliferation of basal-like breast cancer cell line MDA-MB-468[J]. J Chin Integr Med, 2008,6(4):399-404
	叶媚娜, 陈红风 . 黄芪注射液对basal-like型乳腺癌细胞MDA-MB-468增殖的影响[J]. 中西医结合学报, 2008,6(4):399-404
[6]	Gusterson BA, Ross DT, Heath VJ, Stein T . Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer[J]. Breast Cancer Res, 2005,7(4):143-148 doi: 10.1186/bcr1041
[7]	Langerфd A, Zhao H, Borgan Ф, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Bфrresen-Dale AL, Jeffrey SS . TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer[J]. Breast Cancer Res, 2007,9(3):R30 doi: 10.1186/bcr1675
[8]	Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM , Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004,10(16):5367-5374 doi: 10.1158/1078-0432.CCR-04-0220
[9]	Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM . The molecular portraits of breast tumors are conserved across microarray platforms[J]. BMC Genomics, 2006,( 7):96
[10]	van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P . Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome[J]. Am J Pathol, 2002,161(6):1991-1996 doi: 10.1016/S0002-9440(10)64476-8
[11]	Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R , Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis[J]. Lab Invest, 2002,82(11):1525-1533 doi: 10.1097/01.LAB.0000038508.86221.B3

Related Articles 15

[1]	Ofer Baranovitch, Meirav Wolff-Bar, Meora Feinmesser, Chen Sade-Zaltz, Ilan Tsarfaty, Victoria Neiman. Searching for the emotional roots of breast cancer: A cross-disciplinary analysis integrating psychology, Chinese medicine, and oncology biomarkers. Journal of Integrative Medicine, 2022, 20(1): 57-64.
[2]	Fatemeh Sadat Hasheminas, Seyed Mehdi Hashemi, Azizallah Dehghan, Fariba Sharififar, Mohammad Setayesh, Pegah Sasanpour, Mojtaba Tasbandi, Mahboobeh Raeiszadeh. Effects of a Plantago ovata-based herbal compound in prevention and treatment of oral mucositis in patients with breast cancer receiving chemotherapy: A double-blind, randomized, controlled crossover trial. Journal of Integrative Medicine, 2020, 18(3): 214-221.
[3]	Carlos R. Oliveira, Daniel G. Spindola, Daniel M. Garcia, Adolfo Erustes, Alexandre Bechara, Caroline Palmeira-dos-Santos, Soraya S. Smaili, Gustavo J.S. Pereira, André Hinsberger, Ezequiel P. Viriato, Maria Cristina Marcucci, Alexandra C.H.F. Sawaya, Samantha L. Tomaz, Elaine G. Rodrigues, Claudia Bincoletto. Medicinal properties of Angelica archangelica root extract: Cytotoxicity in breast cancer cells and its protective effects against in vivo tumor development. Journal of Integrative Medicine, 2019, 17(2): 132-140.
[4]	Syed Nasir Abbas Bukhari, Fahad Hussain, Hnin Ei Thu, Zahid Hussain. Synergistic effects of combined therapy of curcumin and Fructus Ligustri Lucidi for treatment of osteoporosis: cellular and molecular evidence of enhanced bone formation. Journal of Integrative Medicine, 2019, 17(1): 38-45.
[5]	Lizhou Liu, Simone Petrich, Blair McLaren, Lyndell Kelly, G. David Baxter. An integrative Tai Chi program for patients with breast cancer undergoing cancer therapy: Study protocol for a randomized controlled feasibility study. Journal of Integrative Medicine, 2018, 16(2): 99-105.
[6]	Gloria Gronowicz, Eric R. Secor Jr., John R. Flynn, Liisa T. Kuhn. Human biofield therapy does not affect tumor size but modulates immune responses in a mouse model for breast cancer. Journal of Integrative Medicine, 2016, 14(5): 389-399.
[7]	Mukherjee Avinaba, Sikdar Sourav, Bishayee Kausik, Paul Avijit, Ghosh Samrat, Boujedaini Naoual, Rahman Khuda-Bukhsh Anisur. Ethanolic extract of Thuja occidentalis blocks proliferation of A549 cells and induces apoptosis in vitro. Journal of Chinese Integrative Medicine, 2012, 10(12): 1451-1459.
[8]	Dao-fang Ding , Song-pu Wei, Xiao-feng Li , Xiao-gang Zhang , Hong-sheng Zhan , Tie-li Duan , Yue-long Cao. Inhibition effect of osthole on proliferation of rat chondrocytes. Journal of Chinese Integrative Medicine, 2012, 10(12): 1413-1418.
[9]	Li Zhang , Tao Wu , Jun-ming Chen , Li-li Yang , Hai-yan Song , Guang Ji. Danshensu inhibits acetaldehyde-induced proliferation and activation of hepatic stellate cell-T6. Journal of Chinese Integrative Medicine, 2012, 10(10): 1155-.
[10]	Han Xiang-hui, Ye Yi-yi, Guo Bao-feng, Liu Sheng. Effects of platycodin D in combination with different active ingredients of Chinese herbs on proliferation and invasion of 4T1 and MDA-MB-231 breast cancer cell lines. Journal of Chinese Integrative Medicine, 2012, 10(1): 67-75.
[11]	Bao Tan, Hai-lian Shi, Guang Ji, Lan Lu, Ai-li Cao, Song-shan Shi, Jian-qun Xie. Antiproliferative effects of essential oil of a compound Chinese herbal medicine Weiqi Decoction on AGS cells. Journal of Chinese Integrative Medicine, 2011, 9(5): 558-564.
[12]	Zhao-hui Chu, Xiao-hua Liang, Xin-li Zhou, Ruo-fan Huang, Qiong Zhan, Jing-wei Jiang. Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway. Journal of Chinese Integrative Medicine, 2011, 9(5): 533-538.
[13]	Bo Yang, Xue-chun Lu, Feng Zhang, Yang Liu, Hong-li Zhu. Inhibitory effects of traditional Chinese herbal medicine Tanreqing injection on proliferation of leukemia cells in vitro and the potential mechanisms. Journal of Chinese Integrative Medicine, 2011, 9(4): 414-422.
[14]	Mei-qun Cao, Zheng-zhi Wu, Wei-kang Wu. Identification of salivary biomarkers in breast cancer patients with thick white or thick yellow tongue fur using isobaric tags for relative and absolute quantitative proteomics. Journal of Chinese Integrative Medicine, 2011, 9(3): 275-280.
[15]	Mei-na Ye, Hong-feng Chen, Rui-juan Zhou, Ming-juan Liao. Effects of Astragalus polysaccharide on proliferation and Akt phosphorylation of the basal-like breast cancer cell line. Journal of Chinese Integrative Medicine, 2011, 9(12): 1339-1346.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2]	Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3]	Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4]	SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5]	Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6]	Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7]	Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8]	Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9]	Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10]	Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239

Group	n	OD value
Group	n	MDA-MB-231	MDA-MB-468
Control	5	0.87±0.01	0.43±0.02
1 g/mL Astragalus injection	5	0.57±0.10^*□	0.28±0.02^*□
0.1 g/mL Astragalus injection	5	0.96±0.02	0.46±0.05
40 μg/mL formononetin	5	0.37±0.05^*△□	0.15±0.02^*△□
20 μg/mL formononetin	5	0.60±0.09^*□	0.15±0.01^*△□
10 μg/mL formononetin	5	0.65±0.06^*□	0.20±0.01^*△□
80 μg/mL astragaloside Ⅳ	5	0.71±0.06^*△▲	0.33±0.10^*△▲
40 μg/mL astragaloside Ⅳ	5	0.73±0.03^*△▲	0.32±0.01^*△▲
20 μg/mL astragaloside Ⅳ	5	0.86±0.09	0.40±0.01

Group	n	OD value
Group	n	MDA-MB-231	MDA-MB-468
Control	5	0.87±0.01	0.43±0.02
1 g/mL Astragalus injection	5	0.59±0.05	0.28±0.02
40 μg/mL formononetin	5	0.38±0.05	0.15±0.02
80 μg/mL astragaloside Ⅳ	5	0.71±0.06	0.35±0.05
Astragaloside Ⅳ︰formononetin
1︰1	5	0.33±0.03^*△□	0.16±0.03^*△□
1︰2	5	0.42±0.08^*△□	0.13±0.07^*△□
1︰4	5	0.25±0.08^*△▲□	0.11±0.06^*△□
2︰1	5	0.35±0.02^*△□	0.24±0.04^*□
4︰1	5	0.56±0.05^*□	0.30±0.05^*
8︰1	5	0.70±0.07	0.32±0.09^*

Group	n	p-Akt Thr308 （Fluorescence value）		p-Akt Ser473 （Fluorescence value）
Group	n	1 d	2 d	1 d	2 d
Control	5	3.17±0.31	6.28±0.51	1.43±0.27	2.13±0.36
Astragalus injection	5	2.29±0.29^*	4.64±0.96^*	1.42±0.26	2.07±0.10
Formononetin	5	2.35±0.46^*	3.74±0.39^*△	1.08±0.10^*	1.81±0.25^*
Astragaloside Ⅳ	5	2.39±0.41^*	4.62±0.80^*	1.27±0.22^*	2.28±0.31
Astragaloside Ⅳ plus formononetin	5	2.52±0.45^*	4.00±0.20^*△	1.11±0.09^*	1.67±0.14^*

Group	n	p-Akt Thr308 (Fluorescence value)		p-Akt Ser473 (Fluorescence value)
Group	n	1 d	2 d	1 d	2 d
Control	5	4.46±0.75	3.95±0.44	2.80±0.48	2.75±0.40
Astragalus injection	5	3.86±0.68	3.10±0.41^*	2.68±0.45	2.20±0.27^*
Formononetin	5	3.19±0.37^*	3.05±0.33^*	2.48±0.48	2.01±0.04^*
Astragaloside Ⅳ	5	4.27±0.66	3.70±0.45^*	2.44±0.44	2.40±0.28^*
Astragaloside Ⅳ plus formononetin	5	3.67±0.54^*	2.58±0.19^*▲	2.64±0.39	2.10±0.08^*

Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines

RichHTML

PDF (PC)

Like